Treating HFrEF: Challenges Faced

Slides:



Advertisements
Similar presentations
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Advertisements

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Addressing the Challenges in Primary and Secondary Stroke Prevention
Prior Trials of RAAS Inhibitors
CLINICAL DILEMMAS IN HEART FAILURE:
Emerging Concepts in Heart Failure
EMPHASIS-HF Extended Follow-up
Current State of Hyperkalemia Management
Chronic Hepatitis C Virus Infection
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.
Preventing SCD With a WCD: Reviewing the Results of the VEST Trial
Heart Rate, HF Admissions, and Readmissions
A CASE CHALLENGE IN HFrEF:
PCP Perspectives Clinical Considerations in Hyperkalemia
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
Patient-Centered Care in Cystic Fibrosis
Cost Effectiveness and Optimal Outcomes in HF
Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy
Optimal Use of New Fentanyl Formulations for BTCP in Asia
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Lessons Learned In Opioid Treatment From the Pain Action Consulting Team.
Heart Failure Prevention: Mission Impossible?
An Update on PCSK9 Inhibitors
Figure 7 European Society of Cardiology 2016
Treatment Options to Consider
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Exploring Emerging Treatments for Hyperkalemia
Preventing Heart Failure Readmission and Progression
Antithrombotic Protection in CAD and HF
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Evaluating New Therapies in HF
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
The Importance of Getting the Dose Right in HF
Multidisciplinary Management of Hyperkalemia:
Overcoming Clinical Inertia
Case #1 Case #1 (cont) Case #1 (cont)
Revisiting the Pharmacoeconomics of HF
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Challenging the Myths in Heart Failure With Reduced Ejection Fraction
Identifying Strategies for Improving Outcomes in Patients With CTEPH
CAD and HF Often Coexist
Managing HF in Primary Care
Iron Deficiency in Heart Failure
Extraordinary Cases in VTE
Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.
Treating Atypical Hemolytic Uremic Syndrome A Case Discussion
Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.
Assessing the Burden of Hyperkalemia
Breaking Down the Data in Hyperkalemia
Maria R. Costanzo et al. JCHF 2016;4:
An Update on PCSK9 Inhibitors
Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.
Assessing the Burden of Hyperkalemia
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Rational Pharmacotherapy Selection for Insomnia
PCSK9 Inhibitors and Statin Intolerance
Uptitration of Medications in HF: Start Low but Aim High and Stay High
In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?
Managing HF in Primary Care
Top Tips in Evidence-Based Care for HFrEF
Key Data on Improving Outcomes in HF Patients
RAASi Enabling in the Modern Era
Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.
Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.
What Do the Guidelines Say About The Role of the HF Nurse?
Diagnosing HFpEF: What Every Cardiologist Needs to Know
Presentation transcript:

Treating HFrEF: Challenges Faced

Recommendation for Implantable Cardioverter Defibrillator in Patients With HF

Terminology in Heart Failure: What Does It Mean?

ESC Guidelines: Treatment of Symptomatic HFrEF

Extensive Therapies for Patients With HFrEF in Select Patients

ESC Guidelines: Recommendations for ARNI Use

Prescribing Information for Sacubitril/Valsartan: European Label

PARADIGM-HF: Primary and Secondary Outcomes

PARADIGM-HF: Adverse Events

ESC Guidelines: Recommendations for ARNI Use

Examining Why Recommended Therapies Are Not Provided: Implementation Science

Barriers to Uptitration of HF Therapies

ARNI Use in Patients With HFrEF

Titration of Medications in HFrEF: Implementing Evidence-Based HFrEF Therapy

Managing Hypokalemia/Hyperkalemia in HF

Hyperkalemia: Observations From BIOSTAT-CHF

Technology and Transplantation in HF Management

Potential New Drugs in the Pipeline for HF Management

Historical Development of Drug Therapy in HFrEF

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.